Trial · NCT03001076
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) | Placebo | 4.99 | Standard Error 2.299 | percent change | |
| Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) | Bempedoic Acid | -23.46 | Standard Error 1.945 | percent change | |
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | Placebo | 5.19 | Standard Error 2.202 | percent change | |
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | Bempedoic Acid | -18.38 | Standard Error 1.668 | percent change | |
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | Placebo | 2.88 | Standard Error 1.553 | Percent change | |
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | Bempedoic Acid | -15.11 | Standard Error 1.282 | Percent change | |
| Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB) | Placebo | 4.74 | Standard Error 1.786 | Percent change | |
| Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB) | Bempedoic Acid | -14.58 | Standard Error 1.497 | Percent change | |
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | Placebo | 2.088 | Inter-Quartile Range -32.143 to 49.224 | Percent change | |
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | Bempedoic Acid | -32.521 | Inter-Quartile Range -55.556 to 10.714 | Percent change | |
| Percent Change From Baseline to Week 12 in Triglycerides (TGs) | Placebo | 9.23 | Standard Error 4.218 | Percent change | |
| Percent Change From Baseline to Week 12 in Triglycerides (TGs) | Bempedoic Acid | 4.70 | Standard Error 3.068 | Percent change | |
| Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C) | Placebo | -1.38 | Standard Error 1.389 | percent change | |
| Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C) | Bempedoic Acid | -7.27 | Standard Error 1.214 | percent change | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | TEAEs | 39 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Bempedoic Acid | TEAEs | 88 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Non-serious TEAEs | 18 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Bempedoic Acid | Non-serious TEAEs | 46 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Serious TEAEs | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Bempedoic Acid | Serious TEAEs | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03001076/results